Beyond inflammation: exploring CAR-based cell therapy for fibrostenosing Crohn’s disease
Abstract
Fibrostenosing Crohn’s disease (FSCD) is driven by chronic inflammation, fibroblast activation, extracellular matrix (ECM) deposition and tissue remodeling. Current management includes medical treatment to control inflammation, endoscopic interventions, and surgery to relieve clinically significant strictures. Chimeric antigen receptor (CAR)-based cell therapy represents an emerging research direction that may enable targeted intervention against selected cell populations implicated in fibrogenesis. Unlike approaches focused primarily on inflammatory control, CAR-based strategies can be engineered to recognize selected cellular populations, offering a potential means of directly targeting cells involved in fibrotic remodeling or modulating the local profibrotic microenvironment. By integrating insights from intestinal pathobiology with evidence from other fibrotic settings, we assess candidate cellular targets, therapeutic modalities, and CAR-cell platforms, and consider how these choices should be aligned with lesion accessibility, disease stage, therapeutic objectives, and safety requirements. We further discuss the translational challenges of CAR-based approaches for FSCD.
Related
- Chronic Enteropathy Associated With SLCO2A1 Gene Mutation; Initially Misdiagnosed as Fibrostenosing Crohn's Disease
- Beyond the Bite: Tick Salivary Proteins Targeting Hemostasis and Inflammation; Implications for Cardiovascular Disease
- Modulating Th17-driven inflammation in ulcerative colitis with Chinese medicine: pathways, cytokines and beyond.
- Dual impact of EZH1/2-targeted therapy in HTLV-1-associated inflammation: Direct and indirect mechanisms
- Editorial: Exploring AI’s role in disease prediction and diagnosis through medical big data
BibTeX
@article{sun2026beyond,
title = {{Beyond inflammation: exploring CAR-based cell therapy for fibrostenosing Crohn’s disease}},
author = {Yicheng Sun and Qiwen Chen and Chuyue Zhong and Yuxin Chen and Rui Zhao and Xixi He and Xinli Mao and Jiacheng Li and Zhenqiu Xing and Fang Wu},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1967353},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1967353},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Beyond inflammation: exploring CAR-based cell therapy for fibrostenosing Crohn’s disease
AU - Yicheng Sun
AU - Qiwen Chen
AU - Chuyue Zhong
AU - Yuxin Chen
AU - Rui Zhao
AU - Xixi He
AU - Xinli Mao
AU - Jiacheng Li
AU - Zhenqiu Xing
AU - Fang Wu
PY - 2026
DA - 2026/10/30
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1967353
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1967353
AB - Fibrostenosing Crohn’s disease (FSCD) is driven by chronic inflammation, fibroblast activation, extracellular matrix (ECM) deposition and tissue remodeling. Current management includes medical treatment to control inflammation, endoscopic interventions, and surgery to relieve clinically significant strictures. Chimeric antigen receptor (CAR)-based cell therapy represents an emerging research direction that may enable targeted intervention against selected cell populations implicated in fibrogenesis. Unlike approaches focused primarily on inflammatory control, CAR-based strategies can be engineered to recognize selected cellular populations, offering a potential means of directly targeting cells involved in fibrotic remodeling or modulating the local profibrotic microenvironment. By integrating insights from intestinal pathobiology with evidence from other fibrotic settings, we assess candidate cellular targets, therapeutic modalities, and CAR-cell platforms, and consider how these choices should be aligned with lesion accessibility, disease stage, therapeutic objectives, and safety requirements. We further discuss the translational challenges of CAR-based approaches for FSCD.
SN - 1664-3224
ER -